Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Melanoma 4Neoplasms 3Multiple Myeloma 3Skin Neoplasms 2Polycystic Ovary Syndrome 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Resectable Pancreatic Ductal Adenocarcinoma 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Obesity 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Meningioma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Inflammation 1

Interventions

Doxorubicin 8Cyclophosphamide 4Docetaxel 3Atorvastatin 3dapagliflozin 2Trastuzumab 2Chemotherapy, Adjuvant 2Carvedilol 2nicotinamide-beta-riboside 1empagliflozin 1Tablets 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Paclitaxel 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Mass Spectrometry 1Lisinopril 1Leucovorin 1Lapatinib 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Gene Expression Profiling 1Fluorophotometry 1Filgrastim 1Fenofibrate 1Epirubicin 1Environmental Biomarkers 1Echocardiography 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cardiotoxicity × Tablets × Clear all
NCT05559164 2025-11-14

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Rutgers, The State University of New Jersey

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡